Direct Oral Anticoagulants Materials

DIRECT ORAL ANTICOAGULANTS (DOACs): CHALLENGES AND DECISIONS

Faculty

L. Austin Fredrickson, MD, FACP 

L. Austin Fredrickson is an Associate Professor of Internal Medicine at Northeast Ohio Medical University, where he serves as core faculty and teaches diagnostics, therapeutics, clinical skills, and health humanities. He is board-certified in general internal medicine and practices rural primary care. 

Kimberly Valenta, MD

Kimberly Valenta is a freelance medical writer and editor. She studied chemistry at Mount Holyoke College and medicine at Northwestern University. After completing her anesthesiology residency, she joined the faculty at Stanford University, where she cared for patients and taught medical students and residents. In 2020, she transitioned to writing and editing full-time. She holds a certificate in medical writing and editing from the University of Chicago and is an active member of the American Medical Writers Association.

Kristina (Tia) Neu, RN

Kristina (Tia) Neu is a licensed Registered Nurse and author currently developing in-service training for healthcare professionals. She is a National Board-Certified Health & Wellness and Lifestyle Medicine Coach. Her work experience includes work in several areas of the healthcare profession, including psychiatric nursing, medical nursing, motivational health coaching, chronic case management, dental hygiene, cardiac technician, and surgical technician.

Pamela Sardo, PharmD, BS

Pamela Sardo is a freelance medical writer and licensed pharmacist. She is the founder and principal at Sardo Solutions in Texas. Pam received her BS from the University of Connecticut and her PharmD from the University of Rhode Island. Pam’s career spans many years in retail, clinics, hospitals, long-term care, Veterans Affairs, and managed health care responsibilities across a broad range of therapeutic classes and disease states.

Abstract

Anticoagulant drugs inhibit blood coagulation and reduce the formation of blood clots, thereby lowering the risk of recurrent thrombosis. Despite a long history of available anticoagulants, such as warfarin and heparin, an unmet medical need for additional therapeutic options remains. Direct oral anticoagulants (DOACs), which inhibit thrombin or activated factor X, are frequently prescribed in diverse healthcare settings. Optimizing patient outcomes requires careful consideration of thromboembolic and drug-related bleeding risks, as well as patient-specific factors such as renal function, comorbid conditions, and concomitant medications. Apixaban, dabigatran, edoxaban, and rivaroxaban share overlapping indications but differ in pharmacologic properties, dosing strategies, and safety considerations. Within interdisciplinary care teams, pharmacists and other clinicians contribute complementary expertise to support appropriate DOAC selection, safe use, and patient education regarding dosing, side effects, and drug interactions.

Accreditation Statements

In support of improving patient care, RxCe.com LLC is jointly accredited by the Accreditation Council^TM for Continuing Medical Education (ACCME^®), the Accreditation Council for Pharmacy Education (ACPE^®), and the American Nurses Credentialing Center (ANCC^®), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credits for learning and change.

Joint Universal Activity Number: The Joint Accreditation Universal Activity Numbers assigned to this activity are as follows:

Pharmacists: JA4008424-0000-26-027-H01-P

Pharmacy Technicians: JA4008424-0000-26-027-H01-T

Credits: 2 contact hour(s) (0.2 CEU(s)) of continuing education credit.

Credit Types:

IPCE Credits - 2 Credits

AAPA Category 1 Credit™️ - 2 Credits

AMA PRA Category 1 Credit™️ - 2 Credits

Pharmacy - 2 Credits

Type of Activity: Application

Media: Computer-Based Training (i.e., online courses)

Estimated time to complete activity: 2 contact hour(s) (0.2 CEU(s)), including Course Test and course evaluation.

Release Date: March 13, 2026 Expiration Date: March 13, 2029

Target Audience: This educational activity is for Physicians, Physician Assistants, Pharmacists, and Pharmacy Technicians

How to Earn Credit: From March 13, 2026, through March 13, 2029, participants must:

Read the “learning objectives” and “author and planning team disclosures;”

Take the “Educational Activity Pre-Test;”

Study the section entitled “Educational Activity;” and

Complete the Educational Activity Post-Test and Activity Evaluation. The Educational Activity Post-Test will be graded automatically. Following successful completion of the Educational Activity Post-Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)

CME Credit: Credit for this course will be uploaded to CPE Monitor^® for pharmacists. Physicians may receive AMA PRA Category 1 Credit™️ and use these credits toward Maintenance of Certification (MOC) requirements. Physician Assistants may earn AAPA Category 1 CME credit, reportable through PA Portfolio. All learners shall verify their individual licensing board’s specific requirements and eligibility criteria.

Statement of Need

Thrombotic disorders place a substantial burden on patients and the healthcare system, contributing to significant morbidity and mortality worldwide. Anticoagulant therapy plays a central role in the prevention and treatment of thromboembolic disease. There is a potential gap in knowledge and application regarding the selection of anticoagulation options and the identification of situations in which direct oral anticoagulant (DOAC) therapy may be appropriate or require modification. This activity is intended to address this gap and provide knowledge of the indications and dosing of various DOAC agents, as well as when they may not be appropriate or require modification.

Learning Objectives: Upon completion of this educational activity, participants should be able to:

Identify the indications and dosing for various direct oral anticoagulant (DOAC) agents

Identify the contraindications and potential side effects within the DOAC class

Apply this information to answer patient or prescriber questions

Evaluate patient-specific factors, including renal function, comorbidities, and bleeding risk, that influence DOAC selection and use

Differentiate clinical situations in which DOAC therapy may be inappropriate or require modification

Disclosures

The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP; Kimberly Valenta, MD; Kristina (Tia) Neu, RN; and Pamela Sardo, PharmD, BS. None of the individuals involved in developing this activity has a conflict of interest or financial relationships related to the subject matter. There are no financial relationships or commercial or financial support relevant to this activity to report or disclose by RxCe.com or any of the individuals involved in the development of this activity.

© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.

Educational Activity Pre-Test

When prescribing dabigatran, the prescribing physician and pharmacist should be aware that

dabigatran dosage forms may be substituted on a milligram-to-milligram basis.

multiple dosage forms of dabigatran may be combined to achieve a total dose.

not all dabigatran dosage forms are approved for the same indications or age groups.

dabigatran has no associated risk of causing gastrointestinal (GI) bleeding.

A healthcare team member sees a patient with a new prescription for edoxaban 30 mg PO daily. The patient’s creatinine clearance (CrCl) is >95 mL/min. How should you proceed?

It is appropriate to continue with the prescription and counsel the patient to take the medication as prescribed.

Contact the prescriber regarding alternatives based on the patient’s CrCl.

Counsel the patient that clopidogrel would be a lower-cost therapeutic alternative.

Advise the patient not to take aspirin for at least 2 days before starting on edoxaban.

Which statement best describes peri-procedural management of direct oral anticoagulants (DOACs)?

Bridging with low-molecular-weight heparin is routinely recommended

DOACs should always be stopped 7 days before surgery

Interruption decisions should consider renal function and bleeding risk

Routine DOAC plasma level monitoring is required before procedures

Educational Activity

Direct Oral Anticoagulants (DOACs): Challenges and Decisions

Introduction

Thrombotic disorders place a substantial burden on patients and the healthcare system, contributing to significant morbidity and mortality worldwide. Anticoagulant therapy plays a central role in the prevention and treatment of thromboembolic disease, yet its use requires careful clinical judgment given the competing risks of thrombosis and bleeding. Within interdisciplinary care teams, healthcare professionals collaborate to evaluate anticoagulation options, identify situations in which DOAC therapy may be inappropriate or require modification, and support safe transitions of care. A shared understanding of the similarities and differences among DOAC agents is essential for optimizing therapy, reducing preventable adverse events, and supporting informed discussions with patients and other members of the healthcare team.

Evolution of Anticoagulants

Direct oral anticoagulants (DOACs) have transformed anticoagulation management by offering oral administration, predictable pharmacokinetics, and fixed dosing, with no routine laboratory monitoring required for most patients.^1-4 However, appropriate use of these agents requires a clear understanding of their indications, dosing strategies, contraindications, and safety considerations, as well as patient-specific factors such as renal function, comorbid conditions, and concomitant medications.

The history of anticoagulant development is interesting and reflects the ongoing efforts to balance efficacy, safety, and practicality in clinical care. The first major breakthrough occurred in 1916, when a medical student discovered heparin. Although its anticoagulant properties were recognized early, it would take nearly two decades, and the contributions of Charles Best, known for his role in the discovery of insulin, before heparin was refined and made safe for human use.¹

Warfarin’s origin story began on Midwest dairy farms. In the 1930s, unexplained bleeding and deaths among cattle consuming moldy sweet clover led investigators to discover that a substance in the feed was preventing clotting by reducing prothrombin activity.² Research conducted at the University of Wisconsin–Madison in the latter part of the 1930s revealed that a naturally occurring anticoagulant was formed when coumarin in clover interacted with mold.² Warfarin, a synthetic derivative initially introduced in 1948 as a rodenticide, was approved for human use in 1954.³ Its successful use in President Dwight D. Eisenhower after a myocardial infarction in 1955 helped overcome early hesitation related to its original indication.³

By the 1990s, anticoagulation therapy had advanced further with the introduction of low-molecular-weight heparins (LMWHs).⁴ By shortening the heparin molecule, these agents achieved longer biological half-lives and more predictable anticoagulant responses compared with unfractionated heparin. This translated into fewer laboratory checks, simpler dosing, and the possibility of outpatient treatment for conditions that previously required hospitalization, particularly venous thromboembolism (VTE). Low-molecular-weight heparins did not entirely replace unfractionated heparin, but they expanded the settings in which anticoagulation could be safely delivered.⁴

The search for anticoagulants that were both effective and easier to use continued. Beginning in 2010, DOACs entered clinical practice, targeting specific steps in the coagulation cascade with fixed dosing and fewer routine monitoring requirements.⁵ Their arrival reshaped anticoagulation management across multiple indications.⁵ Today, interdisciplinary care teams navigate this expanding landscape by weighing indications, contraindications, renal function, drug interactions, and bleeding risk to support individualized therapy and favorable patient outcomes.

Thrombotic Disorders

Thrombotic disorders contribute substantially to global morbidity and mortality.⁶ Ischemic heart disease and stroke remain among the leading causes of death and long-term disability, despite advances in primary prevention and the use of traditional anticoagulants.⁶ The burden of stroke, as measured by disability-adjusted life years (DALYs), has continued to rise since 1990, reaching approximately 143 million DALYs and accounting for 6.55 million deaths worldwide in 2019.⁶

Anticoagulation therapy plays a key role in treating certain thrombotic illnesses and avoiding the onset or progression of blood clot formation.⁷ In recent years, clinicians have increasingly adopted direct oral anticoagulants (DOACs), which are administered orally at fixed doses and require less intensive laboratory monitoring in appropriately selected patients.⁷

Classes of Direct Oral Anticoagulants

Direct oral anticoagulants are categorized into 2 main classes: direct thrombin inhibitors and oral direct factor Xa inhibitors.⁴ Within the coagulation cascade, thrombin is a key enzyme responsible for fibrin formation, platelet activation, and clot formation.⁸ Dabigatran (Pradaxa^®) is a direct thrombin inhibitor.^8,9 Factor Xa, which catalyzes the conversion of prothrombin to thrombin, represents another clinical target in coagulation. Apixaban (Eliquis^®), edoxaban (Savaysa^®), and rivaroxaban (Xarelto^®) inhibit factor Xa.^8,10-12 By directly targeting thrombin or factor Xa, these agents interrupt key steps in clot formation and produce more predictable anticoagulant effects compared with vitamin K antagonists.⁸ The full prescribing information for each DOAC agent should be consulted for weight-based dosing recommendations in pediatric patients, guidance for individuals with renal impairment, recommendations for converting to or from parenteral anticoagulants or warfarin, and comprehensive safety and efficacy information. The Table below shows DOAC dosing for specified indications. The Table follows the discussion on direct thrombin inhibitors and factor Xa Inhibitors.

Direct Thrombin Inhibitors

Dabigatran

Dabigatran etexilate is a prodrug that is converted to active dabigatran after absorption from the gastrointestinal tract.⁹ Dabigatran (Pradaxa^®) is available as 75-mg, 110-mg, and 150-mg capsules for adults,⁹ and weight-based dosages are provided for pediatric patients aged 8 to 17.⁹ Dabigatran is also available as 20-mg, 30-mg, 40-mg, 50-mg, 110-mg, and 150-mg pellets in packets for pediatric dosing.¹³

Not all dabigatran dosage forms are approved for the same indications or age groups. Dosage forms should not be substituted on a milligram-to-milligram basis, and multiple dosage forms should not be combined to achieve a total dose.^9,13 Dabigatran capsules must be swallowed whole and should not be crushed, chewed, or opened, as this may increase drug exposure and bleeding risk.¹⁴

Dabigatran is primarily eliminated by the kidneys.^9,13 Renal function should be assessed before initiation and periodically during therapy, and dose adjustment or avoidance may be required in patients with renal impairment.^9,13

There is a boxed warning in the dabigatran full prescribing information regarding the risk of thrombosis associated with premature discontinuation.^9,13 The boxed warning also describes the risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or undergoing spinal puncture. Dabigatran is contraindicated in patients with active pathological bleeding, a history of hypersensitivity to the drug, and those with a mechanical prosthetic heart valve. Dabigatran is not recommended in individuals with triple-positive antiphospholipid syndrome.^9,13

The most common adverse reactions (> 15%) associated with dabigatran include gastrointestinal adverse reactions (such as dyspepsia) and bleeding.^9,13 Clinical trial data indicate a similar risk of major bleeding between dabigatran and warfarin, with a higher incidence of major bleeding observed in patients older than 75 years.^9,13 Idarucizumab is a specific reversal agent for dabigatran and is indicated for patients with life-threatening bleeding or when urgent reversal is required for invasive procedures.¹⁵

Factor Xa Inhibitors

Apixaban

Apixaban is a selective, direct inhibitor of factor Xa that does not require antithrombin III for activity.^10,16 By inhibiting factor Xa, apixaban decreases thrombin generation and thrombus formation. Although it has no direct effect on platelet aggregation, inhibition of thrombin generation indirectly limits platelet activation. Apixaban is available as 2.5-mg and 5-mg tablets.¹⁰

Apixaban is used across multiple clinical settings to reduce the risk of thromboembolic events and is administered at fixed doses in appropriately selected patients.¹⁰ Dose adjustment may be required in certain populations, including patients with impaired renal function, low body weight, or advanced age, depending on the indication.¹⁰ Apixaban undergoes hepatic metabolism and is not recommended in patients with severe hepatic impairment. Concomitant use with strong dual inhibitors or inducers of CYP3A4 and P-glycoprotein may alter drug exposure and should be avoided or managed according to prescribing information.¹⁰

There is a boxed warning regarding the increased risk of thrombosis associated with premature discontinuation of apixaban.¹⁰ The boxed warning also describes the risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or undergoing spinal puncture.¹⁰ Apixaban is contraindicated in active pathological bleeding or a history of hypersensitivity to the drug. It is not recommended for use in patients with prosthetic heart valves or for use in patients with triple-positive antiphospholipid syndrome.¹⁰

The most common adverse events associated with apixaban (>1%) are bleeding-related events.¹⁰ In patients experiencing life-threatening or uncontrolled bleeding, andexanet alfa is an approved reversal agent for apixaban. When andexanet alfa is not available, supportive measures and non-specific reversal strategies may be considered based on clinical judgment.¹⁰

Edoxaban

Edoxaban is a selective, direct inhibitor of factor Xa that does not require antithrombin III for activity.¹¹ By inhibiting factor Xa, edoxaban reduces thrombin generation and thrombus formation. Although it has no direct effect on platelet aggregation, inhibition of thrombin generation indirectly limits thrombin-mediated platelet activation. Edoxaban is available as 15-mg, 30-mg, and 60-mg tablets.¹¹

Edoxaban is administered at fixed doses in appropriately selected patients, with dose adjustment required in certain populations.¹¹ Because edoxaban is substantially eliminated by the kidneys, renal function should be assessed before initiation and periodically during therapy.¹¹ In patients with nonvalvular atrial fibrillation, edoxaban demonstrates reduced efficacy in those with creatinine clearance greater than 95 mL/min and is not recommended in this population. Dose reduction is required in patients with moderate renal impairment, low body weight, or when used concomitantly with certain P-glycoprotein inhibitors. Edoxaban is not recommended in patients with severe hepatic impairment.¹¹

There is a boxed warning regarding reduced efficacy in patients with nonvalvular atrial fibrillation and creatinine clearance greater than 95 mL/min.¹¹ The boxed warning also describes the increased risk of thrombosis associated with premature discontinuation of edoxaban and the risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or undergoing spinal puncture. Edoxaban is contraindicated in patients with active pathological bleeding.¹¹ It is not recommended for use in patients with prosthetic heart valves or in individuals with triple-positive antiphospholipid syndrome.¹¹

In patients with nonvalvular atrial fibrillation, the most common adverse reactions associated with edoxaban (≥5%) include bleeding and anemia.¹¹ In patients treated for deep vein thrombosis and pulmonary embolism, the most common adverse reactions (≥1%) include bleeding, rash, abnormal liver function tests, and anemia.¹¹ In case of life-threatening or uncontrolled bleeding, andexanet alfa may be used as a reversal agent for factor Xa inhibitors when clinically appropriate. Supportive measures and non-specific reversal strategies should be guided by clinical judgment when specific reversal agents are not available.¹¹

Rivaroxaban

Rivaroxaban is a selective, direct oral inhibitor of factor Xa that does not require antithrombin III for activity.¹² By inhibiting factor Xa, rivaroxaban reduces thrombin generation and thrombus formation, thereby limiting clot development.¹² Rivaroxaban is available as 2.5-mg, 10-mg, 15-mg, and 20-mg oral tablets and as a 1-mg/mL oral suspension after reconstitution. The full prescribing information should be consulted for weight-based dosing recommendations in pediatric patients.¹²

Rivaroxaban is administered at fixed doses in appropriately selected patients, with dose adjustments required in certain populations.¹² Because rivaroxaban is partially eliminated by the kidneys, renal function should be assessed before initiation and periodically during therapy. Dose adjustment or avoidance may be necessary in patients with renal impairment, depending on the indication.¹² Rivaroxaban undergoes hepatic metabolism and is not recommended in patients with moderate to severe hepatic impairment. Concomitant use with strong combined P-glycoprotein and CYP3A4 inhibitors or inducers may significantly alter rivaroxaban exposure and should be avoided or managed as prescribed.¹²

There is a boxed warning regarding the increased risk of thrombosis associated with the premature discontinuation of rivaroxaban.¹² The boxed warning also describes the risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or undergoing spinal puncture.¹² Rivaroxaban is contraindicated in patients with active pathological bleeding or a history of hypersensitivity to the drug. It is not recommended for use in patients with prosthetic heart valves or in individuals with triple-positive antiphospholipid syndrome.¹²

In adult patients, the most common adverse reaction associated with rivaroxaban (>5%) is bleeding.¹² In pediatric patients, the most common adverse reactions (>10%) include bleeding, cough, vomiting, and gastroenteritis.¹² In cases of life-threatening or uncontrolled bleeding, andexanet alfa is an approved reversal agent for rivaroxaban. When andexanet alfa is not available, supportive measures and non-specific reversal strategies may be considered based on clinical judgment.¹²

Approved indications and dosing for each DOAC are summarized in the Table below; the following sections highlight key pharmacologic and clinical considerations relevant to agent selection and safe use.

Table

DOAC Dosing in Adults with Specified Indications

Specified Indication	Dabigatran9	Apixaban10	Edoxaban11	Rivaroxaban12
Prevention of stroke and systemic embolism in NVAF	CrCl >30 mL/min: 150 mg PO BID | CrCl 15-30 mL/min: 75 mg PO BID	5 mg PO BID*	CrCl 50–95 mL/min: 60 mg PO daily | CrCl 15–50 mL/min: 30 mg PO daily | Do not use if CrCl >95 mL/min	CrCl >50 mL/min: 20 mg PO daily with evening meal | CrCl ≤50 mL/min: 15 mg PO daily with evening meal
DVT prophylaxis after hip or knee surgery	Hip replacement only: CrCl >30 mL/min: 110 mg PO 1–4 h after surgery (after hemostasis), then 220 mg PO daily for 28–35 days	2.5 mg PO BID | Hip: 35 days; Knee: 12 days	—	10 mg PO daily (Hip: 35 days; Knee: 12 days; with or without food)
Treatment of DVT and PE	CrCl >30 mL/min: 150 mg PO BID after 5–10 days of parenteral anticoagulation	10 mg PO BID x 7 days, then 5 mg PO BID	60 mg PO daily after 5–10 days of parenteral anticoagulation | 30 mg PO daily if CrCl 15–50 mL/min or body weight ≤60 kg or with certain P-gp inhibitors†	CrCl ≥15 mL/min: 15 mg PO BID with food x 21 days, then 20 mg PO daily with food
Prevention of recurrent DVT and PE	CrCl >30 mL/min: 150 mg PO BID (after previous treatment)	2.5 mg PO BID (after ≥6 months of treatment)	—	10 mg PO daily (after ≥6 months of standard anticoagulant treatment; CrCl ≥15 mL/min)
VTE prophylaxis in acutely ill medical patients	—	—	—	10 mg PO daily (in hospital and after discharge for 31–39 days; CrCl ≥15 mL/min)
Prevention of cardiovascular events in CAD or PAD	—	—	—	2.5 mg PO BID + aspirin 75–100 mg PO daily (with or without food)

Abbreviations: BID = twice daily; CAD = coronary artery disease; CrCl = creatinine clearance; DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; PAD = peripheral artery disease; PE = pulmonary embolism; PO = by mouth; P-gp = P-glycoprotein; VTE = venous thromboembolism.

* Apixaban dose reduction (NVAF): use 2.5 mg PO BID in patients with ≥2 of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.

† Edoxaban “certain P-gp inhibitors” (per label language): dose reduction applies when used with certain concomitant P-gp inhibitor medications in the DVT/PE indication.

^§and PE

Discussion

Indication Similarities

Although direct oral anticoagulants (DOACs) share oral administration, fixed dosing, and rapid onset of action (generally within 1 to 3 hours of ingestion), overlapping indications do not imply clinical equivalence.⁸ As shown in the Table above, each DOAC is indicated for nonvalvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), and pulmonary embolism (PE) in adults. However, agent selection should account for patient-specific factors and labeled limitations.⁸ Healthcare professionals should refer to the full prescribing information to confirm indication-specific dosing, contraindications, and transition guidance. Additional distinctions across agents, including use in other diagnoses (see Table above), pediatric populations, transitions to or from warfarin or parenteral anticoagulants, and perioperative discontinuation, may influence initial agent selection and ongoing management.^8,17-19

Agent Selection and Ongoing Management

With the availability of numerous DOAC agents and the expanding list of indications for their use, selecting the most appropriate DOAC for a patient can be challenging.^18,19 There are many factors that will affect DOAC selection:^18,19

Patient comorbidities: renal and hepatic function, signs/symptoms of bleeding

Drug interactions

Patient compliance/adherence

Patient preferences

Clinical outcomes data

Patient characteristics

Quality‐of‐life considerations

Cost of DOAC therapy

DOAC Monitoring Challenges and Special Populations

Patients receiving DOAC therapy remain at risk of increased bleeding due to inhibition of coagulation pathways.^20,21 Although all DOACs are associated with bleeding risk, available evidence suggests that the incidence and pattern of bleeding vary by agent. Apixaban has demonstrated a more favorable overall bleeding profile in several analyses, while rivaroxaban has been associated with higher rates of gastrointestinal bleeding in some populations.²⁰ Although routine lab monitoring is not required, testing may be helpful in selected clinical situations where assessment of drug presence or accumulation could influence management. These situations include suspected overdose, thrombotic or bleeding events, acute stroke, trauma, renal impairment, and planned surgical or invasive procedures. Use in patients with obesity (≥120 kg) or low body weight (≤50 kg) may also warrant additional evaluation.²² Available data suggest that apixaban and edoxaban maintain favorable efficacy and safety profiles in patients with low body weight, while apixaban and rivaroxaban appear reasonable options in patients with obesity, although evidence remains limited at extreme body weights.²³

The optimal laboratory assay for assessing DOAC exposure may not be available at all institutions. Selection of the test depends on assay availability, the clinical question being addressed (drug presence versus drug concentration), and the result turnaround time. Because no specific DOAC plasma concentration has been shown to reliably predict perioperative bleeding risk, routine preprocedural measurement of DOAC levels is not recommended by major professional societies.²² Targeted laboratory assessment in these situations may support clinical decision-making, but routine coagulation monitoring is not required during stable DOAC therapy.²²

Use in Children

In 2021, the US Food and Drug Administration (FDA) approved rivaroxaban and dabigatran for the treatment of pediatric VTE.^9,12,17 The European Medicines Agency (EMA) has also approved these drugs for the same indication.¹⁷ However, as pediatricians gain experience with these drugs, they must be mindful of pediatric-specific considerations where DOAC treatments are not recommended or are limited, such as the following:^9,12,17

Children outside the age and size ranges

Children with active cancer, moderate-to-severe renal impairment, and significant hepatic dysfunction (Child-Pugh C)

Children with prosthetic heart valves, antiphospholipid antibody syndrome, or complex single ventricle physiology

Pregnancy and Breastfeeding

Studies show that VTE risk may increase fivefold during pregnancy and the first 6 weeks after childbirth.²⁴ For pregnant women with a history of VTE or with multiple risk factors (such as thrombophilia), LMWH is the first-line treatment.^24,25 Data supporting the use of DOACs during pregnancy are limited, and breastfeeding is generally not recommended during anticoagulation therapy.^24,25 Decisions to prescribe or continue antithrombotic agents other than heparin or aspirin should be made by the healthcare team, including specialists in perinatal medicine, cardiology, or hematology.”²⁴

Patients with Risk for Gastrointestinal Bleeding

In patients at elevated risk for gastrointestinal bleeding, concomitant use of a proton pump inhibitor may reduce the risk of upper gastrointestinal bleeding, particularly in older adults and those receiving dabigatran.²³ Additional safety considerations include the presence of indwelling epidural or spinal catheters and the concomitant use of non-steroidal anti-inflammatory drugs, antiplatelet agents, or other anticoagulants. Lower DOAC doses may be recommended in patients receiving P-glycoprotein inhibitors.⁸ Thrombocytopenia has been reported with these medications, although its clinical significance remains uncertain.⁴

Interruption and Peri-Procedural Management

Another challenge in DOAC management is determining when to discontinue or interrupt DOAC treatment.²⁰ Beyond recommendations tied to specific indications, such as treatment duration for DVT with rivaroxaban, interruption of DOAC therapy before an invasive procedure or surgery requires individualized assessment. Factors influencing this decision include the agent’s half-life, creatinine clearance, procedural bleeding risk, and patient-specific factors such as prior bleeding history, renal function, and active malignancy.^19,20 Healthcare professionals should evaluate patient comorbidities and remain vigilant for unexpected adverse events when managing peri-procedural anticoagulation.^24,26 Bridging with heparin or low-molecular-weight heparin is generally not recommended for average-risk patients receiving DOAC therapy, as the interruption periods are short and bridging may increase the risk of bleeding.^24,26 In patients at very high risk of thromboembolism (e.g., very recent VTE), bridging may be considered.^24,26

Drug Interactions

The hepatic enzyme CYP3A4 plays an important role in the metabolism of rivaroxaban and apixaban, and all DOACs are substrates of the P-glycoprotein transporter system.²⁷ Enzyme inducers can reduce DOAC plasma concentrations and may increase the risk of thromboembolic events. Strong P-glycoprotein inducers that may lower DOAC concentrations include rifampicin, carbamazepine, phenytoin, and phenobarbital. Other examples include dexamethasone, St. John's wort, and some antivirals, such as tipranavir and rifabutin.²⁷

Conversely, inhibitors of CYP3A4 or P-glycoprotein can increase DOAC plasma concentrations, potentially increasing the risk of bleeding.²⁸ Strong P-gp inhibitors include amiodarone, clarithromycin, cyclosporine, ketoconazole, ritonavir, and verapamil. These drugs can significantly alter the pharmacokinetics of other medications that are substrates of P-glycoprotein by decreasing their clearance, which can lead to increased drug concentrations and a higher risk of toxicity.²⁸ In the presence of clinically significant drug interactions, reassessment of anticoagulation strategy, dosing, or agent selection may be warranted.¹⁹

Reversal Agents

In rare cases, a reversal agent may be appropriate. There are two reversal agents for DOACs.²⁹ Coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) is a modified human factor Xa protein indicated for patients treated with rivaroxaban or apixaban when reversal is needed due to life-threatening or uncontrolled bleeding. It is not approved for the treatment of bleeding with any other factor Xa inhibitors.³⁰ Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment (Fab) indicated for the reversal of dabigatran’s anticoagulant effects.^31,32 In patients who experience a bleeding event, resumption of anticoagulation should be individualized based on bleeding severity, location, and thromboembolic risk. In many cases, restarting anticoagulation after stabilization is associated with a reduced risk of thromboembolic events and mortality compared with permanent discontinuation.²⁰

Future Research

Large, randomized trials of DOACs in patients with morbid obesity are needed. Despite limited evidence, DOACs are commonly used to treat venous thromboembolism in this population. A recent analysis of Medicare and commercial claims databases found that, among 34,910 patients with morbid obesity (BMI ≥40 kg/m2) receiving anticoagulation for non-valvular atrial fibrillation, 63.4% were treated with a DOAC.³³

Ongoing research continues to evaluate the role of DOACs in less common clinical scenarios. ClinicalTrials.gov lists a study in Italy examining DOAC use in unusual-site venous thrombosis, including splanchnic, cerebral, retinal, ovarian, and renal vein thrombosis.³⁴ Another trial is evaluating DOAC use in women who experience heavy menstrual bleeding.³⁵

Clinical Pearls for Patient Discussions

Clinical pearls in this section highlight common patient and prescriber questions encountered in collaborative practice, as well as practical strategies to support the safe and effective use of direct oral anticoagulants within interdisciplinary teams.

Pharmacists frequently serve as points of contact for patients and other healthcare professionals when questions arise about DOAC therapy. Key discussions may include the following:^36,37

Patients should not discontinue anticoagulant therapy without first discussing it with their prescribing clinician and should take the medication exactly as prescribed.

Bruising may occur during treatment; patients should be advised to report any unusual, persistent, or severe bleeding promptly.

All physicians, dentists, and pharmacists involved in a patient’s care should be informed of current anticoagulant therapy.

Patients should inform healthcare professionals of all over-the-counter medications, supplements, and herbal products they are using.

Patients should notify clinicians if they are pregnant, planning to become pregnant, or breastfeeding.

Anticoagulants should not be substituted or interchanged without the clinician's guidance.

Aspirin or other antiplatelet agents may not be required once a DOAC is initiated unless there is a specific clinical indication.

Lifestyle considerations, including alcohol use and activities that may increase bleeding risk, should be discussed.

Patients should take reasonable precautions to reduce the risk of injury.

Encouraging questions can support patient understanding, adherence, and shared decision-making.

An interprofessional approach is essential to safe anticoagulation management. Key elements associated with improved anticoagulation care include effective care transitions between healthcare settings, medication adherence, patient communication and engagement, and thorough medication reconciliation and review. These elements are particularly important during transitions of care, when the risk of medication errors and unintended duplications is highest.³⁹

In a systematic review and meta-analysis of randomized controlled trials, patients receiving DOACs who experienced major bleeding had a reported fatality was 7.57% (range of 6.53%–8.68%).³⁸ Each healthcare team member can play an important role in supporting patient safety by identifying potential drug interactions, dosing concerns, or duplicated anticoagulant therapy. For example, if a prescription of a DOAC is received concurrently with enoxaparin or another low-molecular-weight heparin, the pharmacist should promptly contact the primary care physician to discuss the treatment plan.

Summary

Education on DOACs remains essential to supporting patient safety and optimizing clinical outcomes. Although DOACs offer practical advantages over traditional anticoagulants, their use requires careful consideration of patient-specific factors, including renal function, comorbid conditions, bleeding risk, and concomitant medications. Differences among agents, despite overlapping indications, may influence both initial selection and ongoing management.

Appropriate DOAC use also depends on recognizing clinical situations in which therapy may require modification or avoidance, such as in patients with certain comorbidities, during transitions of care, or in the setting of planned procedures or potential drug interactions. Pharmacists play an important role in applying this knowledge to address patient and prescriber questions, identify safety concerns, and support interdisciplinary communication. Through informed evaluation and collaboration, healthcare professionals can help reduce preventable adverse events and support appropriate anticoagulation therapy across care settings.

References

Lim GB. Milestone 1: Discovery and purification of heparin. Nat Rev Cardiol. Published online December 14, 2017. doi:10.1038/nrcardio.2017.171

Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141(6):757-63. doi: 10.1111/j.1365-2141.2008.07119.x

Lim GB. Milestone 2: Warfarin: from rat poison to clinical use. Nat Rev Cardiol. Published online December 14, 2017. doi:10.1038/nrcardio.2017.172

Franchini M, Liumbruno G, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfus. 2016;14:175-84. doi: 10.2450/2015.0096-15

Tucker M, Padarti A. Thrombocytopenia due to direct oral anticoagulation and low-molecular-weight heparin. Cureus. 2021;13(10):e18757. doi: 10.7759/cureus.18757

Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021

Lefebvre M, Cachanado M, Chatellier G, Emmerich J. Effects on mortality of extended versus short-term anticoagulation in venous thromboembolism: a systematic review and meta-analysis of randomized trials. Res Pract Thromb Haemost. 2025;9(4):102928. Published 2025 Jun 9. doi:10.1016/j.rpth.2025.102928

Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. Semin Thromb Hemost. 2019;45(5):490-501. doi: 10.1055/s-0039-1692703

PRADAXA- dabigatran etexilate mesylate capsule. Prescribing Information. Boehringer Ingelheim Pharmaceuticals Inc. Updated June 25, 2025. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9

ELIQUIS- apixaban tablet, film coated ELIQUIS 30-DAY STARTER PACK- apixaban kit. Prescribing Information. E.R. Squibb & Sons, L.L.C. Updated April 17, 2025. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b

SAVAYSA- edoxaban tosylate tablet, film coated. Prescribing Information. Daiichi Sankyo Inc. Updated July 10, 2025. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66

XARELTO- rivaroxaban tablet, film coated XARELTO- rivaroxaban tablet, film coated XARELTO- rivaroxaban kit XARELTO- rivaroxaban granule, for suspension. Prescribing Information. Janssen Pharmaceuticals, Inc. Updated January 16, 2026. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610

PRADAXA- dabigatran etexilate pellet. Prescribing Information. Boehringer Ingelheim Pharmaceuticals Inc. Updated June 27, 2025. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ac0a64a-8666-45f7-9d4f-40fd894f7e6d

DABIGATRAN- dabigatran etexilate capsule. Prescribing Information. Novadoz Pharmaceuticals LLC. Updated February 6, 2026. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f79088b-b353-485a-9df4-6f5088f5bd0f

Jarrett JB, Gimbar RP. Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal. Am Fam Physician. 2017;95(12):798-800.

APIXABAN tablet, film coated. Prescribing Information. Amneal Pharmaceuticals of New York LLC. Updated May 23, 2024. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a60552-374d-4b8b-a8ce-ceae252ea5ba

Whitworth H, Raffini L. Practical Considerations for Use of Direct Oral Anticoagulants in Children. Front Pediatr. 2022;10:860369. Published 2022 Apr 1. doi:10.3389/fped.2022.860369

Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020;9(13):e017559. doi:10.1161/JAHA.120.017559

Julia S, Uprichard J. Direct oral anticoagulants: a quick guide. Eur Cardiol. 2017;12(1): 40–45. doi: 10.15420/ecr.2017:11:2

Douketis JD, Spyropoulos AC. Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review. JAMA. 2024;332(10):825–834. doi:10.1001/jama.2024.12708

Lucà F, Oliva F, Abrignani MG, et al. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. J Clin Med. 2023;12(18):5955. Published 2023 Sep 13. doi:10.3390/jcm12185955

Dunois C. Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines. 2021;9(5):445. doi: 10.3390/biomedicines9050445

Ballestri S, Romagnoli E, Arioli D, et al. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. Adv Ther. 2023;40(1):41-66. doi:10.1007/s12325-022-02333-9

Roberti R, Iannone LF, Palleria C, et al. Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Front Pharmacol. 2021;12:684638. Published 2021 May 26. doi:10.3389/fphar.2021.684638

James AH, Sugrue R, Federspiel JJ. Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents. Clin Obstet Gynecol. 2023;66(1):196-207. doi:10.1097/GRF.0000000000000740

Barnes GD, Mouland E. Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. Prog Cardiovasc Dis. 2018;60(6):600-606. doi:10.1016/j.pcad.2018.03.002

Bauters T, Dadkhah A. Clinically Relevant Drug Interactions in HCT. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, et al., editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 31. doi: 10.1007/978-3-031-44080-9_31. Accessed March 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK608254/

Coumau C, Csajka C. A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs. Clin Pharmacokinet. 2025;64(6):849-863. doi:10.1007/s40262-025-01514-3

White K, Faruqi U, Cohen AAT. New agents for DOAC reversal: a practical management review. Br J Cardiol. 2022;29(1):1. Published 2022 Jan 12. doi:10.5837/bjc.2022.001

ANDEXXA- andexanet alfa injection, powder, lyophilized, for solution. Prescribing Information. AstraZeneca Pharmaceuticals LP. Updated May 23, 2025. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c

PRAXBIND- idarucizumab injection. Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. Updated January 23, 2024. Accessed March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7400f8a-dcf4-a6df-6d07-983081b1bf34

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019 Jun;94(6):697-709. doi: 10.1002/ajh.25475. Epub 2019 Apr 16. PMID: 30916798.

Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J Clin Med 2020;9:163

DOAC in unusual site venous thrombosis (DUST). ClinicalTrials.gov. Updated May 4, 2020. https://clinicaltrials.gov/ct2/show/NCT03778502?term=DOAC&draw=2&rank=9. Accessed September 27, 2022.

Prospective comparison of incidence of heavy menstrual bleeding in women treated with direct oral anticoagulants. ClinicalTrials.gov. Updated January 14, 2022. https://clinicaltrials.gov/ct2/show/NCT04477837?term=DOAC&cond=menstrual&draw=2&rank=1. Accessed September 26, 2022.

Sylvester KW, Chen A, Lewin A, Fanikos J, Goldhaber SZ, Connors JM. Optimization of DOAC management services in a centralized anticoagulation clinic. Res Pract Thromb Haemost. 2022;6(3):e12696. Published 2022 May 5. doi:10.1002/rth2.1269

Hawes EM. Patient Education on Oral Anticoagulation. Pharmacy (Basel). 2018;6(2):34. Published 2018 Apr 20. doi:10.3390/pharmacy6020034

Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015;13(11):2012-20. doi: 10.1111/jth.13139

Damen NL, Van den Bemt BJF, Hersberger KE, et al. Creating an Interprofessional guideline to support patients receiving oral anticoagulation therapy: a Delphi exercise. Int J Clin Pharm. 2019;41(4):1012-1020. doi:10.1007/s11096-019-00844-0

DISCLAIMER

The information provided in this course is general in nature, and it is designed solely to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment, and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice.

Healthcare professionals must consult their employer, healthcare facility, hospital, or other organization for guidelines, protocols, and procedures to follow. The information provided in this course does not replace those guidelines, protocols, and procedures, but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits.

Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses is constantly changing. Any person taking this course understands that such a person must make an independent review of medication information before any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only, and such uses are not endorsed hereby.

Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course or course material.

© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.

RxCe.com

© RxCe.com LLC 2025: All rights reserved.